• Ascendis Pharma flagged new long-term pooled data for TransCon PTH in chronic hypoparathyroidism for presentation at ASBMR 2026.
• The five-year analysis is set to show treated patients reached normalized bone mass and bone microarchitecture.
• Separate ASBMR posters are scheduled to highlight improved growth, physical functioning, and limb alignment in children receiving navepegritide for achondroplasia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060915PRIMZONEFULLFEED9840494) on October 06, 2026, and is solely responsible for the information contained therein.